[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie expect the aesthetics market in China to fully recover?
### Assistant: AbbVie expects the aesthetics market in China to fully recover in the second half of the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What improvements were seen in the aesthetics market in China in February and March?
### Assistant: In February and March, AbbVie saw improvement in the aesthetics market in China.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie expect the recovery in the aesthetics market in China to sustain throughout the year?
### Assistant: AbbVie expects the recovery in the aesthetics market in China to sustain throughout the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is high inflation impacting consumer demand in Canada and the U.K. for AbbVie's aesthetics business?
### Assistant: High inflation is impacting consumer demand in Canada and the U.K. for AbbVie's aesthetics business.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie view the stability of the aesthetics market in the rest of Europe?
### Assistant: The rest of Europe seems stable for AbbVie's aesthetics business.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Can AbbVie clarify the price decline for I&I and how it relates to volumes?
### Assistant: AbbVie clarifies that the price decline for I&I is expected to be down high single digits.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Should we expect high single-digit declines in pricing for I&I to continue for the rest of the quarter?
### Assistant: It is unclear from the given text whether high single-digit declines in pricing for I&I will continue for the rest of the quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie expect pricing to stabilize quarter-over-quarter for I&I?
### Assistant: AbbVie expects pricing for I&I to stabilize quarter-over-quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's pipeline strategy beyond Skyrizi and Rinvoq?
### Assistant: AbbVie's pipeline strategy beyond Skyrizi and Rinvoq is to look for assets in areas where there is still a significant opportunity to restate standard of care.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie plan to address the products 154 and 157 that did not meet expectations?
### Assistant: AbbVie did not provide specific information on how they plan to address the products 154 and 157 that did not meet expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What opportunities does AbbVie see for restating the standard of care in other areas of their pipeline?
### Assistant: AbbVie sees opportunities to restate the standard of care in other areas of their pipeline where they believe there is still a significant opportunity.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is AbbVie considering M&A opportunities for pipeline expansion?
### Assistant: AbbVie's stance on considering M&A opportunities for pipeline expansion is not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie navigate the increased FTC scrutiny when considering M&A?
### Assistant: The given text does not provide information on how AbbVie navigates the increased FTC scrutiny when considering M&A.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's outlook for the growth of Skyrizi and Rinvoq in the early part of the next decade?
### Assistant: AbbVie expects strong growth for Skyrizi and Rinvoq in the early part of the next decade.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie assess the impact of Skyrizi and Rinvoq on the immunology market?
### Assistant: Skyrizi and Rinvoq have restated the immunology market across most of the segments that AbbVie operates in.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors does AbbVie consider when looking for assets to drive growth in the immunology market?
### Assistant: AbbVie considers assets that have the potential to restate standard of care when looking for growth opportunities in the immunology market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie view the potential for restating the standard of care in other segments of the immunology market?
### Assistant: AbbVie views the potential for restating the standard of care in other segments of the immunology market as significant.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie balance pipeline development with the potential for M&A in the current regulatory environment?
### Assistant: The given text does not provide information on how AbbVie balances pipeline development with the potential for M&A in the current regulatory environment.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What industry is AbbVie in?
### Assistant: AbbVie is in the pharmaceutical industry.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some of the mechanisms that AbbVie is looking for in their products?
### Assistant: AbbVie is looking for different mechanisms in their products to deliver high performance.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did the 154 platform perform in terms of efficacy?
### Assistant: The 154 platform performed well in terms of efficacy.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: At what dose did the 154 platform show effects of steroids on biomarkers?
### Assistant: The effects of steroids on biomarkers were seen at the highest dose of the 154 platform.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Why did AbbVie believe that the 154 platform would not have a competitive profile?
### Assistant: AbbVie believed that the 154 platform would not have a competitive profile based on the way regulators would view the label for such products.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What kind of products does AbbVie hope to introduce in the next decade?
### Assistant: AbbVie hopes to introduce next-generation immunology assets as follow-on products in the next decade or early into the next decade.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What progress is AbbVie making in finding new mechanisms for their products?
### Assistant: AbbVie is making progress in finding new mechanisms for their products.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is AbbVie exploring opportunities internally or externally?
### Assistant: AbbVie is exploring opportunities both internally and externally.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Does AbbVie believe they have freedom to operate in the immunology market?
### Assistant: AbbVie believes they have freedom to operate in the immunology market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the common requirement for negotiating contracts to gain access to indications in the industry?
### Assistant: The common requirement for negotiating contracts to gain access to indications in the industry is a level of price concession.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie's price concession compare to others in the industry?
### Assistant: AbbVie's price concession is on the lower end compared to others in the industry.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors will drive the price going forward for AbbVie's products?
### Assistant: The price going forward for AbbVie's products will be primarily driven by volume.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expectation for price increases in each quarter this year?
### Assistant: The expectation for price increases in each quarter this year is high single-digit.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How might changes to the rebating structure impact big incumbent products?
### Assistant: Changes to the rebating structure may impact big incumbent products by potentially removing the rebate wall.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is there a chance of proposed legislative changes becoming law?
### Assistant: There is a chance of proposed legislative changes becoming law.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are there any collateral impacts on Skyrizi or Rinvoq since Humira biosimilars have launched?
### Assistant: There may be collateral impacts on Skyrizi or Rinvoq since Humira biosimilars have launched.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Will there be a shift of patients from Skyrizi and Rinvoq to biosimilars in the second half of the year?
### Assistant: There may be a shift of patients from Skyrizi and Rinvoq to biosimilars in the second half of the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie differentiate their brands from competitors?
### Assistant: AbbVie differentiates their brands by conducting head-to-head trials and demonstrating distinctiveness.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How many head-to-head trials has AbbVie conducted for Skyrizi?
### Assistant: AbbVie has conducted four head-to-head trials for Skyrizi.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are there any upcoming trials for Skyrizi?
### Assistant: There are upcoming trials for Skyrizi.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's strategy for maintaining the distinctiveness of their brands?
### Assistant: AbbVie's strategy for maintaining the distinctiveness of their brands is through differentiation and demonstrating efficacy.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie differentiate their products from biosimilars?
### Assistant: AbbVie differentiates their products from biosimilars through their unique mechanisms and distinctiveness.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the impact of biosimilars on AbbVie's market share?
### Assistant: Biosimilars have an impact on AbbVie's market share.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are there any plans to counter the competition from biosimilars?
### Assistant: There may be plans to counter the competition from biosimilars.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie plan to retain patients on their brands despite biosimilar competition?
### Assistant: AbbVie plans to retain patients on their brands despite biosimilar competition through their distinctiveness and efficacy.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the perspective on the potential restructuring of the PDMs at AbbVie?
### Assistant: The perspective on the potential restructuring of the PDMs at AbbVie is that it is not imminent and there is no concern about a fundamental structural change relative to the two core products, Skyrizi and Rinvoq.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How would the disappearance of the rebate approach impact AbbVie's INI products?
### Assistant: The disappearance of the rebate approach would impact AbbVie's INI products by eliminating the fairly reasonable rebate load that currently exists. However, AbbVie is not concerned about this change and believes they would still perform well under a different basis of competition.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is AbbVie concerned about a fundamental structural change relative to Skyrizi and Rinvoq?
### Assistant: AbbVie is not concerned about a fundamental structural change relative to Skyrizi and Rinvoq. They believe these two products are very distinctive and do not anticipate significant impacts from Humira biosimilars on their performance.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the performance of Rinvoq in the United States compared to TNF?
### Assistant: Rinvoq is already in the United States step behind TNF, but it is performing well due to the expansion of second and third lines in that space.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Does AbbVie anticipate a knock-on effect of emergent biosimilars on Skyrizi and Rinvoq?
### Assistant: AbbVie does not anticipate a knock-on effect of emergent biosimilars on Skyrizi and Rinvoq.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has the volatility in the marketplace affected AbbVie's conversations with potential targets?
### Assistant: The volatility in the marketplace has not significantly changed AbbVie's conversations with potential targets.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Has there been a shift in the bid-ask spread and the willingness of boards and management to consider deals?
### Assistant: There has not been a shift in the bid-ask spread and the willingness of boards and management to consider deals.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Have biotech companies become more willing to engage with players like AbbVie?
### Assistant: Biotech companies may be more willing to engage with players like AbbVie due to the difficulty in raising money for biotech companies.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the interest level in engagement with potential targets in the biotech area?
### Assistant: The interest level in engagement with potential targets in the biotech area is similar to what it has been for the last 12 to 24 months.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are valuations for good assets still relatively high in the biotech sector?
### Assistant: Valuations for good assets in the biotech sector are still relatively high.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What data points are expected for Navitoclax and Teliso-V this year?
### Assistant: The data points expected for Navitoclax and Teliso-V this year are not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are AbbVie's expectations for Navitoclax and Teliso-V?
### Assistant: The expectations for Navitoclax and Teliso-V are not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie hoping to see from Navitoclax and Teliso-V?
### Assistant: AbbVie's hopes for Navitoclax and Teliso-V are not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Teliso-V relate to the next-gen ABBV-400?
### Assistant: The relationship between Teliso-V and the next-gen ABBV-400 is not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are the succession planning plans for Rick Gonzalez at AbbVie?
### Assistant: The succession planning plans for Rick Gonzalez at AbbVie are not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is there an updated timeline for Rick Gonzalez's departure considering the Humira bench?
### Assistant: There is no updated timeline for Rick Gonzalez's departure mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Can we expect an announcement regarding succession planning this year?
### Assistant: There is no mention of an announcement regarding succession planning this year in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is AbbVie looking for a successor in 2024 or later?
### Assistant: There is no mention of AbbVie looking for a successor in 2024 or later in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie approach finding the right kind of asset for potential transactions?
### Assistant: AbbVie approaches finding the right kind of asset for potential transactions by looking for assets in the biotech area that meet their needs and can provide significant value.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors make an asset attractive to AbbVie for a potential transaction?
### Assistant: Factors that make an asset attractive to AbbVie for a potential transaction include its ability to provide significant value and justify a high valuation and return.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie negotiate transactions in the biotech area?
### Assistant: AbbVie negotiates transactions in the biotech area by engaging with potential targets and pursuing opportunities that meet their criteria.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the probability of being able to negotiate a transaction in the current environment?
### Assistant: The probability of being able to negotiate a transaction in the current environment is not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie justify valuations for good assets in the biotech sector?
### Assistant: AbbVie justifies valuations for good assets in the biotech sector by ensuring that the asset can provide significant value to justify the high valuation and return.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What opportunities is AbbVie currently looking for in terms of potential transactions?
### Assistant: AbbVie is currently looking for opportunities in the biotech sector for potential transactions, but specific details are not mentioned in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie determine if an asset will provide significant value to justify a high valuation and return?
### Assistant: AbbVie determines if an asset will provide significant value to justify a high valuation and return by evaluating its potential and assessing its ability to meet their needs and generate substantial value.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's focus on Navitoclax and Teliso-V?
### Assistant: AbbVie's focus is on Navitoclax and Teliso-V.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are the goals for Navitoclax in combination with JAK-2 and myelofibrosis?
### Assistant: The goals for Navitoclax in combination with JAK-2 and myelofibrosis are to be better than monotherapy with a JAK-2 in that space and to improve spleen size and symptoms like abdominal pain, fullness, fever, and fatigue.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What symptoms is AbbVie aiming to improve with Navitoclax?
### Assistant: AbbVie is aiming to improve symptoms like abdominal pain, fullness, fever, and fatigue with Navitoclax.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What additional benefits have been observed with Navitoclax?
### Assistant: Additional benefits observed with Navitoclax include an improvement in bone marrow fibrosis and a decrease in variant allelic frequency.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When can we expect a readout for Navitoclax?
### Assistant: A readout for Navitoclax is expected by mid-year or so.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the indication for Teliso-V in lung cancer?
### Assistant: The indication for Teliso-V is lung cancer.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What designation does Teliso-V have in lung cancer?
### Assistant: Teliso-V has Breakthrough Therapy designation in lung cancer.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the ORR for Teliso-V in earlier data cuts?
### Assistant: In earlier data cuts, Teliso-V has shown an ORR (Overall Response Rate) above 50%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Teliso-V compare to standard of care in the second and third-line setting?
### Assistant: Teliso-V has shown higher response rates compared to standard of care in the second and third-line setting.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is there a potential for accelerated approval for Teliso-V?
### Assistant: There is a potential for accelerated approval for Teliso-V.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What data will be presented at ASCO regarding Teliso-V?
### Assistant: Data regarding Teliso-V will be presented at ASCO.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's perspective on Teliso-V in the CMAT population?
### Assistant: AbbVie's perspective on Teliso-V in the CMAT population is that it gets very good responses in CMAT highs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the potential for the topo warhead in the CMAT population?
### Assistant: The potential for the topo warhead in the CMAT population is that it seems to give deeper and more durable responses.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What leadership changes are happening at AbbVie?
### Assistant: There are leadership changes happening at AbbVie.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What criteria is AbbVie using for the succession plan?
### Assistant: The criteria AbbVie is using for the succession plan is to ensure a successful and smooth transition, complete the transition for Humira biosimilars in the U.S., prove the biosimilar erosion is predictable, and ensure the candidate to succeed the current CEO is ready.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the current status of the transition for Humira biosimilars in the U.S.?
### Assistant: The transition for Humira biosimilars in the U.S. is going well so far.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is the growth platform performing despite headwinds?
### Assistant: The growth platform is performing well despite headwinds, such as Imbruvica and the economy's impact on aesthetics.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When can we expect the growth rate to increase significantly for the growth platform?
### Assistant: The growth rate for the growth platform is expected to increase significantly as we move into '24.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When does AbbVie expect to return to robust growth?
### Assistant: AbbVie expects to return to robust growth in '25.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What role will the current CEO assume during the transition to a new CEO?
### Assistant: The current CEO is expected to assume the Executive Chairman role for a period of time during the transition to a new CEO.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How long does AbbVie expect the transition to take?
### Assistant: The length of the transition to a new CEO is not specified.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expectation for biosimilar erosion?
### Assistant: The expectation for biosimilar erosion is that it will be predictable.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What capacity is the current CEO willing to stay in?
### Assistant: The current CEO is willing to stay in any capacity desired by the board for whatever length they would like.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the current expectation for the transition to a new CEO?
### Assistant: The current expectation is that the transition to a new CEO will not occur in '23.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the next question from?
### Assistant: The next question is from Evan Seigerman with BMO Capital.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the market share of Skyrizi in the psoriasis indication?
### Assistant: The market share of Skyrizi in the psoriasis indication is 30%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How much further can Skyrizi penetrate the dermatology market?
### Assistant: Skyrizi can penetrate the dermatology market further as there is still significant headroom for growth. The company believes that Skyrizi can capture roughly 50% of the dynamic share, meaning one out of every two patients.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are there any other assets in earlier development related to CF programs?
### Assistant: There are no other assets in earlier development related to CF programs mentioned in the text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is AbbVie done investing in CF programs?
### Assistant: AbbVie is discontinuing the CF program, indicating that they are done investing in this area.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How fast is Skyrizi growing in Crohn's and UC?
### Assistant: Skyrizi is growing rapidly in both Crohn's and UC, although the exact growth rate is not specified in the text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What impact does PsA have on the international markets?
### Assistant: PsA has a significant impact on the international markets as it is treated by dermatologists. The text suggests that the treatment of PsA by derms is a last remaining gap, indicating that it has a positive impact on the dermatology market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How confident is AbbVie in the 5.7% heme-onc guide for Imbruvica?
### Assistant: AbbVie is confident in the 5.7% heme-onc guide for Imbruvica.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What competitive pressures does Imbruvica face?
### Assistant: Imbruvica faces significant competitive pressure from drugs like Calquence, Venclexta, and Brukinsa.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What level of pricing pressure can be expected for Imbruvica throughout the year?
### Assistant: The text does not specify the exact level of pricing pressure that can be expected for Imbruvica throughout the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is there a potential for further step down in the guide for Imbruvica later in the year?
### Assistant: It is unlikely that there will be a significant step-down in the guide for Imbruvica later in the year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Could the delay with 951 push Imbruvica out?
### Assistant: The delay with 951 is not mentioned as a factor that could push Imbruvica out.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is AbbVie seeing significant pricing pressure in the market?
### Assistant: AbbVie is not seeing significant pricing pressure in the market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has the market for Imbruvica been over time?
### Assistant: The market for Imbruvica has been suppressed over time but is now showing signs of normalization, with positive growth observed for the first time in three years.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the new patient share for Imbruvica?
### Assistant: The text does not specify the exact new patient share for Imbruvica.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What factors have been putting pressure on the new patient share for Imbruvica?
### Assistant: The new patient share for Imbruvica has been under pressure from competitive launches of drugs like Calquence, Venclexta, and Brukinsa.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has the market for Skyrizi been in the rest of the world?
### Assistant: The text does not provide information on the market for Skyrizi in the rest of the world.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What impact does PsA have on the dermatology market?
### Assistant: PsA has a significant impact on the dermatology market as it is treated by dermatologists and fills a remaining gap in the market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How significant is the impact of Skyrizi in the international markets?
### Assistant: The impact of Skyrizi in the international markets is described as significant.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is there any disruption expected in the psoriasis market?
### Assistant: No significant disruption is expected in the psoriasis market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How long will it take for the total market share of Skyrizi to move towards the in-play share?
### Assistant: It will take many years for the total market share of Skyrizi to move towards the in-play share.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the significance of the CF program discontinuation?
### Assistant: The discontinuation of the CF program is significant as it means AbbVie is no longer investing in this area.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Are there any other options for the CF program?
### Assistant: The text does not mention any other options for the CF program.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the significance of the C2 corrector not working in the CF program?
### Assistant: The C2 corrector tested in the CF program did not work, and there is no backup option, leading to the discontinuation of the program.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the pricing pressure for Imbruvica in the U.S. market?
### Assistant: The text does not specify the pricing pressure for Imbruvica in the U.S. market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has the market for Imbruvica been affected by Calquence, Venclexta, and Brukinsa launches?
### Assistant: The market for Imbruvica has been affected by competitive launches of drugs like Calquence, Venclexta, and Brukinsa, which have put pressure on the new patient share.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the role of Michael in AbbVie?
### Assistant: Michael's role in AbbVie is not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the Vice Chairman and President of AbbVie?
### Assistant: The Vice Chairman and President of AbbVie is not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the significance of U.S. Humira for AbbVie's earnings?
### Assistant: The significance of U.S. Humira for AbbVie's earnings is that if U.S. Humira performs well and AbbVie outperforms in '23, then the trough in earnings could occur in '24.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: When could the trough occur for AbbVie's earnings?
### Assistant: The trough for AbbVie's earnings could occur in '24 if U.S. Humira does better and AbbVie outperforms in '23.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the minimum expected earnings for AbbVie?
### Assistant: The minimum expected earnings for AbbVie is not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie view the delay of Imbruvica-951?
### Assistant: AbbVie does not consider the delay of Imbruvica-951 to be a variable that would push the trough in earnings.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the Vice President of Investor Relations at AbbVie?
### Assistant: The Vice President of Investor Relations at AbbVie is Liz Shea.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie consider the impact of peer reports?
### Assistant: AbbVie considers the impact of peer reports in the interest of time during the conference call.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the last question from in the conference call?
### Assistant: The last question in the conference call is from Geoff Meacham with Bank of America.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the question about Imbruvica in the follow-up?
### Assistant: The question in the follow-up is about any changes to the outlook following the MCL/MDL withdrawal.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does AbbVie expect the outlook to change following the MCL/MDL withdrawal?
### Assistant: AbbVie does not expect the outlook to change significantly following the MCL/MDL withdrawal.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected impact of the withdrawals on Imbruvica's value?
### Assistant: The withdrawals of MCL/MDL are not expected to have a material impact on Imbruvica's value.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How do physicians typically handle patients on Imbruvica?
### Assistant: Physicians typically continue patients on Imbruvica rather than switching them to another product.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the market intelligence regarding physicians' actions with Imbruvica?
### Assistant: The market intelligence suggests that physicians do not need to switch patients off of Imbruvica.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the role of Roopal Thakkar in AbbVie?
### Assistant: Roopal Thakkar's role in AbbVie is Vice President, Global Regulatory Affairs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected phase 3 readout for follicular lymphoma?
### Assistant: The phase 3 readout for follicular lymphoma is expected later this year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Will the MCL outcomes affect the readout for follicular lymphoma?
### Assistant: It is not clear if the MCL outcomes would be reflected in the readout for follicular lymphoma.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is AbbVie's focus in relation to follicular lymphoma?
### Assistant: AbbVie's focus in relation to follicular lymphoma is on Epcoritamab, a dual engager, and the expected actions for DL BCL.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected action for DL BCL with Epcoritamab?
### Assistant: The expected action for DL BCL with Epcoritamab is not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What data is expected to be presented at ASCO regarding FL and DL BCL?
### Assistant: Data regarding FL and DL BCL in combinations with Epcoritamab is expected to be presented at ASCO.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How can one access a replay of the conference call?
### Assistant: To access a replay of the conference call, one can visit AbbVie's website.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Where can one find the replay of the conference call on AbbVie's website?
### Assistant: The replay of the conference call can be found on AbbVie's website at investors.abbvie.com.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the Chairman and Chief Executive Officer of AbbVie?
### Assistant: The Chairman and Chief Executive Officer of AbbVie is Rick Gonzalez.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the role of Jeff Stewart in AbbVie?
### Assistant: Jeff Stewart's role in AbbVie is Executive Vice President, Chief Commercial Officer.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the Senior Vice President, Chief Financial Officer of AbbVie?
### Assistant: The Senior Vice President, Chief Financial Officer of AbbVie is Scott Reents.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the date and time of the Cigna Group's Q1 2023 Earnings Call?
### Assistant: The date of the Cigna Group's Q1 2023 Earnings Call is May 05, 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who is the Vice President of Investor Relations at Cigna Group?
### Assistant: The Vice President of Investor Relations at Cigna Group is Ralph Giacobbe.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who will be speaking during the conference call?
### Assistant: The speakers during the conference call will be David Cordani, the Cigna Group's Chairman and Chief Executive Officer, and Brian Evanko, the Chief Financial Officer.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What topics will be covered during the call?
### Assistant: The topics that will be covered during the call include the first quarter financial results and the updated financial outlook for 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Where can the earnings release be found?
### Assistant: The earnings release can be found in the investor relations section of thecignagroup.com.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What financial measures does Cigna Group use to describe their financial results?
### Assistant: Cigna Group uses adjusted income from operations and adjusted revenues to describe their financial results.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are the risks and uncertainties mentioned in the statement?
### Assistant: The risks and uncertainties mentioned in the statement are those that could cause actual results to differ materially from their current expectations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What accounting guidance did Cigna Group adopt for long-duration insurance contracts?
### Assistant: Cigna Group adopted amended accounting guidance for long-duration insurance contracts (LDTI) and related amendments.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Has there been any material impact to Cigna Group's prior results due to the accounting change?
### Assistant: There has been no material impact to Cigna Group's prior results due to the accounting change.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna Group plan to include potential impact of future share repurchases and anticipated dividends in their financial performance comments?
### Assistant: Cigna Group plans to include the potential impact of future share repurchases and anticipated 2023 dividends in their financial performance comments.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Who will be taking over the call after Ralph Giacobbe?
### Assistant: David Cordani, the Chairman and Chief Executive Officer, will be taking over the call after Ralph Giacobbe.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did Cigna Group perform in the first quarter of 2023 in terms of total revenues?
### Assistant: In the first quarter of 2023, Cigna Group delivered $46.5 billion in total revenues.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What was the adjusted earnings per share for the first quarter?
### Assistant: The adjusted earnings per share for the first quarter was $5.41.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Is Cigna Group raising their guidance for adjusted EPS, revenue, and customer growth for 2023?
### Assistant: Yes, Cigna Group is raising their guidance for adjusted EPS, revenue, and customer growth for 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Which divisions of Cigna Group contributed to strong growth in the first quarter?
### Assistant: Evernorth Health Services and Cigna Healthcare contributed to strong growth in the first quarter.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Evernorth and what services does it comprise?
### Assistant: Evernorth is a division of Cigna Group that comprises pharmacy benefit services, specialty pharmacy, and Evernorth Care.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Did Evernorth contribute to the growth of Cigna Group's relationships with employers, health plans, and governmental organizations?
### Assistant: Yes, Evernorth contributed to the growth of Cigna Group's relationships with employers, health plans, and governmental organizations.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Cigna Group's outlook for 2023?
### Assistant: Cigna Group's outlook for 2023 is very good.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna Group address evolving stakeholder needs with their flexible and agile model?
### Assistant: Cigna Group addresses evolving stakeholder needs with a flexible and agile model that provides multiple avenues to deliver and capture value.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna Group deliver and capture value for their stakeholders?
### Assistant: Cigna Group delivers and captures value for their stakeholders through their durable and flexible pharmacy benefit services.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are the key drivers fueling Cigna Group's growth in the first quarter?
### Assistant: The key drivers fueling Cigna Group's growth in the first quarter were not specified in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna Group innovate for their customers, clients, and partners?
### Assistant: Cigna Group innovates for their customers, clients, and partners by leading the way to address evolving stakeholder needs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the full year 2023 guidance for adjusted EPS, revenue, and customer growth?
### Assistant: The full year 2023 guidance for adjusted EPS, revenue, and customer growth was not provided in the given text.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna Group ensure a strong start for Evernorth Health Services and Cigna Healthcare?
### Assistant: Cigna Group ensures a strong start for Evernorth Health Services and Cigna Healthcare through their continued strong performance and long track record of innovation.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What can we expect from the Cigna Group in the future?
### Assistant: From the Cigna Group, we can expect another very good year with strong performance and continued innovation to address evolving stakeholder needs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What percentage of Evernorth's total revenue does specialty pharmacy account for?
### Assistant: Specialty pharmacy accounts for approximately 40% of Evernorth's total revenue.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some examples of the growing needs in virtual care that Evernorth Care addresses?
### Assistant: Evernorth Care addresses the growing needs in virtual care, as well as behavioral health services.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How did Cigna Healthcare perform in terms of revenue and customer growth?
### Assistant: Cigna Healthcare achieved another quarter of revenue and customer growth, with strong performance across its U.S. commercial, U.S. government, and international health businesses.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the medical care ratio for Cigna Healthcare?
### Assistant: The medical care ratio for Cigna Healthcare was 81.3%.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Cigna's U.S. commercial business performing?
### Assistant: Cigna's U.S. commercial business is performing well and is on pace for another good year.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What initiatives have strengthened Cigna's overall competitive position?
### Assistant: Cigna's affordability initiatives have strengthened its overall competitive position.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How is Cigna's Medicare Advantage business performing in terms of growth?
### Assistant: Cigna's Medicare Advantage business is achieving above-market growth in 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Cigna's strategy for expanding its individual and family plan business?
### Assistant: Cigna plans to expand its individual and family plan business in the dynamic individual exchange market.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has Cigna's international health business performed in terms of earnings growth?
### Assistant: Cigna's international health business has had strong earnings growth for the past few years and is expected to continue contributing positively in 2023.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Cigna's outlook for the year in terms of growth and value creation?
### Assistant: Cigna is confident in its increased outlook for the year and expects sustained growth and attractive value creation.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What recent announcements has Cigna made regarding Express Scripts?
### Assistant: Cigna has made recent announcements about how Express Scripts is providing greater affordability, choice, and transparency for clients and customers.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What role do pharmacy services play in medical care?
### Assistant: Pharmacy services play an essential and impactful role in medical care, both for physical and behavioral interventions.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna address the rising cost of prescription drugs?
### Assistant: Cigna addresses the rising cost of prescription drugs by using its differentiated capabilities to create and capture value out of the drug supply chain on behalf of its clients and customers.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is Cigna's model for delivering solutions and care coordination?
### Assistant: Cigna's model for delivering solutions and care coordination is to address specific client needs and expand relationships with its full suite of services and capabilities.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna prioritize choice for its clients while driving down costs?
### Assistant: Cigna prioritizes choice for its clients while driving down costs by enabling and prioritizing choice and advocating for financing models that support cost reduction.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna drive greater affordability, access, transparency, and improved clinical outcomes?
### Assistant: Cigna drives greater affordability, access, transparency, and improved clinical outcomes through innovation and building on its long track record of delivering high-quality and localized health insurance solutions.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the client retention rate for Express Scripts?
### Assistant: Express Scripts has consistently high client retention rates in the mid-90s or higher.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What types of clients does Express Scripts serve?
### Assistant: Express Scripts serves a diverse group of clients, ranging from medium-sized to the largest employers, local health plans to national players, and even the largest government-sponsored programs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Express Scripts advocate on behalf of its clients and customers?
### Assistant: Express Scripts advocates on behalf of its clients and customers, particularly in areas related to financing models.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some key areas of focus for current legislative proposals related to financing models?
### Assistant: Some key areas of focus for current legislative proposals related to financing models include the rising cost of prescription drugs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the commitment of Express Scripts' business model?
### Assistant: The commitment of Express Scripts' business model is to deliver solutions and care coordination that address specific client needs and expand relationships with its full suite of services and capabilities.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Express Scripts prioritize choice for its clients?
### Assistant: Express Scripts prioritizes choice for its clients by enabling and prioritizing choice in pharmacy services.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What are some of the strengths of Express Scripts' supply chain, clinical, and care management programs?
### Assistant: Express Scripts' strengths lie in its supply chain, clinical, and care management programs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What types of clients does Express Scripts win new business from?
### Assistant: Express Scripts wins new business from a diverse range of clients, including medium-sized to the largest employers, local health plans to national players, and even the largest government-sponsored programs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Express Scripts advocate for financing models in the current legislative landscape?
### Assistant: Express Scripts advocates for financing models in the current legislative landscape by expanding its efforts to advocate on behalf of its clients and customers, particularly in areas related to financing models.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What benefit design and financing options does Cigna offer for clients who are the primary financers of their employee benefit programs?
### Assistant: Cigna offers benefit design and financing options for clients who are the primary financers of their employee benefit programs. These options include allowing Cigna to share in the discounts they secure on behalf of their clients, such as rebates or spread pricing.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna share in the discounts they secure on behalf of their clients?
### Assistant: Cigna shares in the discounts they secure on behalf of their clients by allowing them to finance the cost of their programs. This can be done through rebate sharing or spread pricing, where Cigna passes on a portion of the discounts they secure to their clients.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What percentage of rebate dollars are passed through to clients in Cigna's Express Scripts pharmacy benefit service portfolio?
### Assistant: According to the text, over 95% of rebate dollars are passed through to clients in Cigna's Express Scripts pharmacy benefit service portfolio.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: Why do clients choose different financing mechanisms for their pharmacy costs?
### Assistant: Clients choose different financing mechanisms for their pharmacy costs based on their needs for managing risk and greater predictability for their pharmacy costs, as well as their cash flow. They have the option to choose among these models based on what works best for them.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How would limiting the availability and scope of financing options impact employers' health plans and government clients?
### Assistant: Limiting the availability and scope of financing options would result in less choice for thousands of employers' health plans and government clients. This would increase their costs over time and reduce their ability to manage their pharmacy costs effectively.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How does Cigna generate sustainable and attractive margins for their services under different legislative scenarios?
### Assistant: Cigna generates sustainable and attractive margins for their services under different legislative scenarios by leveraging their capabilities, from supply chain to benefit design. They drive competition among drug manufacturers to bring costs down and deliver better health outcomes through their clinical programs.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the expected percentage of Evernorth's 2023 pre-tax adjusted earnings to come from Express Scripts' retention of rebates and retail spread?
### Assistant: The text does not provide an exact percentage of Evernorth's 2023 pre-tax adjusted earnings to come from Express Scripts' retention of rebates and retail spread.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: How has the percentage of income from rebate retention and retail spread trended over time for Cigna?
### Assistant: The text mentions that the percentage of income from rebate retention and retail spread has trended down over time for Cigna. They expect this trend to continue downward.


[INST] <<SYS>>
Use the provided conversation to generate a relevant answer. If the new question is related to the prior context, use that information to provide a more detailed answer. If the new question is not related to prior context, provide a standalone answer.
<<\/SYS>>

### Human: What is the relationship between financing options and service fees for Cigna's clients?
### Assistant: The text states that the financing options provided by Cigna to clients are developed in exchange for lower service fees. This means that if these programs decrease further over time, fee-based income would increase.